Add BrightSurf on Google Email

MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies

Phoenix SENOLYTIX and MD Anderson Cancer Center announced a cross-licensing agreement to further develop inducible switch technologies for use in cell and gene therapies. The partnership will enhance the development of these technologies, which can be used as safety features to regulate cell therapy activity.

GLP-1 receptor agonists and cancer risk in adults with obesity

A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.

SourceJAMA Network·JournalJAMA Oncology·DateAug 21, 2025

New guidance on the management of aromatase inhibitor-associated bone loss in women with hormone-sensitive breast cancer

The International Osteoporosis Foundation has issued an updated joint position statement on managing aromatase inhibitor-associated bone loss in women with hormone-sensitive breast cancer. The guidelines incorporate recent clinical trials and systematic reviews to provide evidence-based treatment algorithms for assessing fracture risk ...

SourceInternational Osteoporosis Foundation·JournalJournal of Bone Oncology·TypeLiterature review·DateAug 18, 2025

Oncology, primary care coordination necessary for best cancer patient outcomes

A new study from the University of Missouri-Columbia highlights the importance of consistent primary care coordination in cancer survivorship care. The research found that only a third of patients consistently saw the same primary care clinician during and after cancer treatment, leading to fragmented care and gaps in patient services.

SourceUniversity of Missouri-Columbia·JournalCurrent Oncology·TypeObservational study·DateAug 13, 2025

The Lancet Gastroenterology & Hepatology: Routine AI assistance may lead to loss of skills in health professionals who perform colonoscopies, study suggests

A study published in The Lancet Gastroenterology & Hepatology found that routine AI assistance during colonoscopies can lead to a decrease in the ability of endoscopists to detect precancerous growths without AI aid. This reduction in skills may impact patient-related outcomes and highlight the need for further research on the long-ter...

SourceThe Lancet·JournalThe Lancet Gastroenterology & Hepatology·TypeObservational study·DateAug 12, 2025

Effective therapy for MDS is vastly underused, especially in female and non-white patients

The study found that only 16% of newly diagnosed patients with MDS on Medicare received HMAs during the period analyzed, with women and non-white patients being less likely to start treatment. The analysis suggests that making changes with existing therapies and administration can have a huge impact on improving outcomes in high-risk MDS.

SourceAmerican Society of Hematology·JournalBlood Neoplasia·DateAug 6, 2025

Challenging over 150 years of cancer immunotherapy: AUN bacteria herald an immune-independent breakthrough

Researchers have discovered a novel microbial consortium called AUN that produces exceptional tumor eradication in both murine and human cancer models. The therapy exhibits high biocompatibility and minimal side effects, offering a long-awaited solution for immunocompromised patients.

SourceJapan Advanced Institute of Science and Technology·JournalNature Biomedical Engineering·DateAug 5, 2025

Chinese Medical Journal study highlights the role of artificial intelligence in prostate cancer management

Recent AI-based models, such as Asian Prostate Cancer Artificial Intelligence and Galen Prostate, optimize screening and reduce unnecessary biopsies. These models use multimodal clinical parameters and convolutional neural networks to detect prostate cancer and identify aggressiveness of cancer cells.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateJul 30, 2025

NTU Singapore and Oxford scientists reveal how cells repair toxic DNA damage linked to cancer and premature ageing

Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.

SourceNanyang Technological University·JournalNucleic Acids Research·TypeExperimental study·DateJul 21, 2025

An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study

A new study published in JAMA Network Open found no statistical relationship between pathologic complete response (pCR) and overall survival in rectal cancer patients. This challenges the FDA's use of pCR as a surrogate endpoint for drug approval, which may lead to treatments being fast-tracked without evidence of improved long-term su...

SourceTulane University·JournalJAMA Network Open·DateJul 17, 2025

Temozolomide and radiation treatment lead to dramatic tumor shrinkage and improvement of hearing in an adult brainstem glioma patient with a rare IDH2 mutation

Researchers successfully treated a patient with a rare IDH2-mutant brainstem astrocytoma using temozolomide and radiation, resulting in significant tumor shrinkage and improved hearing. The patient's unique genetic profile was identified through magnetic resonance spectroscopy and surgical biopsy, allowing for targeted treatment.

SourceNiigata University·JournalFrontiers in Oncology·DateJul 16, 2025

New research in JNCCN offers reassurance about localized prostate cancer prognosis

A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateJul 10, 2025

Cancer screenings continue years after guidelines change to limit unnecessary tests, study finds

Researchers found that it took 13 years for cervical cancer screenings to halve among women over 65, and even longer for prostate cancer screenings to decrease significantly. The study emphasizes the need for more effective tracking mechanisms to identify and reduce inappropriate screening practices.

SourceUniversity of Florida·JournalBMJ Quality & Safety·TypeData/statistical analysis·DateJun 9, 2025